Comparative Pharmacology
Head-to-head clinical analysis: ALPHAZINE versus LOXITANE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALPHAZINE versus LOXITANE.
ALPHAZINE vs LOXITANE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Alpha-2 adrenergic receptor agonist in the central nervous system, reducing sympathetic outflow from the brainstem, leading to decreased peripheral vascular resistance and heart rate.
Loxapine is a typical antipsychotic that exerts its effects primarily by blocking dopamine D2 receptors in the mesolimbic pathway. It also has affinity for serotonin 5-HT2A, histamine H1, alpha1-adrenergic, and muscarinic receptors.
Adults: IM/SC 10 mg every 4 hours as needed, maximum 40 mg/day; IV 5 mg over 1 minute, may repeat in 20-30 minutes, maximum 10 mg.
Oral: Initial 10 mg twice daily; may increase up to 250 mg/day in divided doses. IM: 12.5-50 mg every 4-6 hours.
None Documented
None Documented
5-7 hours; prolonged to 10-15 hours in renal impairment.
12-18 hours (terminal). Steady state achieved within 3-5 days; dosing adjustments for renal/hepatic impairment.
Primarily renal (60-70% unchanged), 20-30% biliary/fecal as metabolites.
Renal excretion accounts for 50-60% (primarily as metabolites, <1% unchanged). Fecal/biliary elimination accounts for 25-35% (via bile).
Category C
Category C
Antipsychotic
Antipsychotic